Experimental flu vaccine with booster enters first human tests
NCT ID NCT07349017
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new influenza vaccine that includes a special booster called BK-01 adjuvant. The goal is to see if it is safe and triggers a strong immune response in adults 18 and older. 160 volunteers will receive either the new vaccine, a standard flu vaccine, or a placebo, and be monitored for 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- influenza vaccine with BK-01 adjuvant
- What this could lead to
- If successful, this could lead to a more effective seasonal flu vaccine that provides better protection against influenza.
- What could go wrong
- This is a very early Phase 1 trial with only 160 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts